GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » HeartBeam Inc (NAS:BEAT) » Definitions » GF Value

BEAT (HeartBeam) GF Value : $0.00 (As of Apr. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is HeartBeam GF Value?

As of today (2025-04-04), HeartBeam's share price is $1.7094. HeartBeam's GF Value is $0.00. Therefore, HeartBeam's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes HeartBeam is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

  1. We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
  2. We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
  3. Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.


HeartBeam  (NAS:BEAT) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

HeartBeam's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=1.7094/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeartBeam GF Value Related Terms

Thank you for viewing the detailed overview of HeartBeam's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartBeam Business Description

Traded in Other Exchanges
N/A
Address
2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
Executives
Richard M Ferrari director, officer: Exec Chm of the BOD 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Urioste George De director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Kenneth Harry Persen officer: Chief Technology Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Robert Paul Eno officer: President 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Michael R Jaff director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Nelson Kenneth Warwick Iii director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard D Brounstein officer: Chief Financial Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Alan Baumel officer: Chief Operating Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 94050
Marga Ortigas-wedekind director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Branislav Vajdic 10 percent owner, officer: Chief Executive Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Willhem Elfrink director 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Jon Patrick Hunt officer: Chief Business Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050